Pipeline

Products		Clinical indication	Region								Licensee
Ripasudil hydrochloride hydrate	K-321	Fuchs endothelial corneal dystrophy	US, etc.				●				Kowa
Ripasudil hydrochloride hydrate/ Brimonidine tartrate	GLA-ALPHA®	Glaucoma and ocular hypertension	Japan, Asia							●	Kowa
DW-1002		ILM staining	Europe, US, etc.							●	DORC
		ILM staining	China						●		DORC
		ILM staining	Japan				●				Wakamoto Pharmaceutical
		ALC staining	Japan				●
		ILM, ERM and PVR membrane staining	Europe, etc.							●	DORC
		ILM staining and ERM staining	US				●				DORC
DW-1001		Ophthalmic treatment agent	Japan		●						ROHTO Pharmaceutical
H-1337		Glaucoma and ocular hypertension	US			●					Developed internally
H-1129		Keratoconjunctival diseases based on immune disorders (details not disclosed)	Japan	●※							Developed internally
DW-5LBT		Neuropathic pain after shingles	US						●		Jointly developed with MEDRx
DWR-2206		Bullous Keratopathy	Japan			●					Jointly developed with ActualEyes

*Currently preparing for clinical trials. Plan to consult with the authorities at the start of Phase II

The Group is engaged in the discovery of new drug candidate compounds with a focus on protein kinase inhibitors. There are various diseases in which protein kinases are relevant, but we are promoting research with a focus on ophthalmic conditions in particular.
Leveraging our drug discovery platform technology, we are actively promoting alliances with other companies.

Our main project consists of the development of signal transmission inhibitors at our research institute (in the research facilities of Mie University) for treatment of ophthalmic, neuropathic, and respiratory conditions. In addition, in terms of joint development with universities, etc., we are expanding indications of our internally developed products and actively moving forward with multiple projects targeting ophthalmic conditions.